Progyny Tops Q3 Estimates, Lifts Full-Year Guidance Midpoint, Adds Record 1.3M Covered Lives
PGNY sits 87% above its 52-week low of $16.1.
Summary
Progyny beat on Q3 with revenue of $341.3M (+8.9%) and EPS of $0.32, raised the midpoint of full-year guidance, and signed a record 1.3 million new covered lives for 2027 with near 100% retention.
Key Events · Earnings and Guidance · PGNY
-
Q3 Beat With Raised Guidance Midpoint
Revenue of $341.3M rose 8.9%, and net income of $26.3M ($0.32 per diluted share) more than doubled from $13.9M. Full-year 2026 guidance calls for $1.365B-$1.385B in revenue and $107.0M-$110.6M in net income, with the midpoint raised.
-
Record 1.3M New Covered Lives
The selling season produced 1.3 million new covered lives and over 85 new clients, the most ever in a single season, with near 100% retention for 2027. Once all clients are live in 2027, the company expects over 660 clients and roughly 8.3 million covered lives.
-
Margin Mix: Gross Up, EBITDA Down
Gross margin expanded 130 bps to 24.5% on care-management efficiencies and lower stock-based compensation. Adjusted EBITDA margin, by contrast, fell 40 bps to 17.1% on planned platform investment.
-
Buyback Running, $51M Left
Nearly 3 million shares were repurchased for $82.7M in Q3. About 5.5 million shares have been bought under the May 2026 program, with roughly $51M of authorization remaining, and 14.3 million shares repurchased since November 2025.
Analysis · PGNY · Industrial Applications And Services
The headline beat is solid: Q3 revenue of $341.3M, up 8.9%, and net income of $26.3M, or $0.32 per diluted share, versus $13.9M a year ago. More important for the thesis, management raised the midpoint of full-year guidance to $1.365B-$1.385B in revenue and $107.0M-$110.6M in net income. The real driver, though, is the selling season: 1.3 million new covered lives and over 85 new clients, the most ever in a single season, with near 100% retention for 2027. Those lives mostly go live in Q1 2027, and once all new clients are live the company expects more than 660 clients and roughly 8.3 million covered lives. That is the setup for 2027 growth, and it explains why the stock's reaction hinges on the guidance raise rather than the backward-looking quarter. Against that, Adjusted EBITDA margin slipped 40 bps to 17.1% on planned platform investment, and the company spent $82.7M buying back nearly 3 million shares in the quarter, leaving about $51M on the current authorization.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PGNY was trading at $30.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $16.10 to $33.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.